Comparison

ERBB3 Antibody

Item no. E10-20254
Manufacturer Enogene
Amount 100 ug/100 ul
Quantity options 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 100 ug/100 ul 100 ug
Category
Type Antibody
Format Liquid
Applications WB, IHC, ELISA
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Alias HER3, LCCS2
Similar products ERBB3
Available
Manufacturer - Applications
WB, IHC, ELISA. Not yet tested in other applications. Determining optimal working dilutions by titration test.
Manufacturer - Conjugate / Tag
This antibody is also available with the following conjugates:
AF350, AF405L, AF405M, AF405S, AF488, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF635, AF647, AF680, AF700, AF750, AF790, APC, AP, Biotin, Cy3, Cy5.5, Cy5, Cy7, FITC, HRP, PE, Magnetic beads (1 um, 2.8 um, 3 um, 4.5 um, 5 um, 10 um, 15 um, 20 um, 30 um, or different size option)
Please contact sales@hoelzel.de for pricing and availability.
Storage Conditions
Store at 4C, for long term storage, store at -20C
Immunogen
Purified recombinant fragment of ERBB3 (aa1175-1275) expressed in E. Coli.
Research Area
Autophagy antibody, Cancer, Cardiovascular, Cell Biology, Epigenetics and Nuclear Signaling, Developmental Biologys, Immunology, Drug Discovery Products, Metabolism, Neuroscience, Signal Transduction, Stem Cells
Background
ERBB3. v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian). This gene encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound protein has a neuregulin binding domain but not an active kinase domain. It therefore can bind this ligand but not convey the signal into the cell through protein phosphorylation. However, it does form heterodimers with other EGF receptor family members which do have kinase activity. Heterodimerization leads to the activation of pathways which lead to cell proliferation or differentiation. Amplification of this gene and/or overexpression of its protein have been reported in numerous cancers, including prostate, bladder, and breast tumors. Alternate transcriptional splice variants encoding different isoforms have been characterized. One isoform lacks the intermembrane region and is secreted outside the cell. This form acts to modulate the activity of the membrane-bound form. Additional splice variants have also been reported, but they have not been thoroughly characterized.
Recommended Dilutions
WB.1/500 - 1/2000.IHC . 1/200 - 1/1000. ELISA. Propose dilution 1/10000.
Formulation Description
Ascitic fluid containing 0.03% sodium azide.
CiteID
EN0013502

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 ug/100 ul
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close